We now have the largest travel commercial portfolio in the globe and that has led us to become a fully integrated profitable company he said of the Emergent deal adding that a resurgence in travel demand postpandemic bodes well for bringing in new travel vaccines like chikungunya Here Chaplin explains the impact of Bavarians Phase 3 failures the promise of its chikungunya vaccine candidate and the companys strategy to become a major vaccine player